Lipum AB (publ) has published the interim report Q1 for the period January-March 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website.
Financial summary January – March 2025
- Other operating income: 492 KSEK (94)
- Result after financial items: -19 010 KSEK (-9 313)
- Cash and cash equivalents as of March 31: 4 262 KSEK (1 473)
Significant events during the period January – March 2025
- Lipum has completed the Phase I study with SOL-116 and is sharing the top-line results
Significant events after the period
- Lipum announces the successful completion and publication of the Clinical Study Report (CSR) for SOL-116 – the findings support further clinical development
CEO Ola Sandborgh comments – “Lipum is currently in a very favorable position”
The year 2025 has started off strong, as we have been able to tie things together and communicate key results from our development program. We have successfully completed our first clinical study involving both healthy volunteers and patients with rheumatoid arthritis (RA), with highly promising results.
This was a Phase 1 study, primarily focused on evaluating the safety, tolerability, and pharmacokinetics of SOL-116. In addition, we conducted exploratory analyses to monitor the levels of bile salt-stimulated lipase (BSSL), the target protein that SOL-116 is designed to bind to in order to exert its effect.
The outcome is as positive as one could reasonably expect from a Phase 1 study. We have therefore obtained the answers we need to move forward to the next step – Phase 2 – where we will evaluate the treatment effect in a broader patient population with RA.
Ola Sandborgh, CEO
Ola Sandborgh comments on the report in a live webcast on April 24 at 09:00 (in Swedish only) link .
The complete report (only in Swedish) is available at www.lipum.se